Dashboard
Manage Tickers

CPRX


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

what-does-the-market-think-about-catalyst-pharmaceuticals-inc
What Does the Market Think About Catalyst ...
10/21/2025 14:00:48

catalyst-pharmaceuticals-board-authorizes-200m-share-repurchase-program
Catalyst Pharmaceuticals Board Authorizes ...
10/01/2025 12:04:13

how-is-the-market-feeling-about-catalyst-pharmaceuticals
How Is The Market Feeling About Catalyst P...
09/09/2025 14:00:31

catalyst-pharmaceuticals-reaches-settlement-with-lupin-to-delay-generic-firdapse-launch-until-2035
Catalyst Pharmaceuticals Reaches Settlemen...
08/25/2025 12:06:03

Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical co...

catalyst-pharmaceuticals-affirms-fy2025-sales-guidance-of-545000m-565000m-vs-561012m-est
Catalyst Pharmaceuticals Affirms FY2025 Sa...
08/06/2025 20:24:01

Catalyst Pharmaceuticals (NASDAQ:CPRX) affirms FY2025 sales outlook from $545.000 million-$565.000 million to $545.000 million-...

catalyst-pharmaceuticals-q2-adj-eps-068-beats-038-estimate-sales-146563m-beat-140418m-estimate
Catalyst Pharmaceuticals Q2 Adj. EPS $0.68...
08/06/2025 20:23:43

Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate...

catalyst-pharmaceuticals-applauds-nccn-guideline-update-adding-lems-diagnosis-and-amifampridine-support-for-sclc-patients
Catalyst Pharmaceuticals Applauds NCCN Gui...
08/06/2025 12:18:20

VGCC antibody testing in conjunction with neurologic consultation can diagnose LEMSAmifampridine may be considered as a support...

Core News & Articles
Earnings Scheduled For August 6, 2025
08/06/2025 08:33:21

is-the-market-bullish-or-bearish-on-catalyst-pharmaceuticals
Is the Market Bullish or Bearish on Cataly...
07/31/2025 20:00:36

peering-into-catalyst-pharmaceuticalss-recent-short-interest
Peering Into Catalyst Pharmaceuticals's Re...
07/14/2025 13:00:32

is-catalyst-pharmaceuticals-gaining-or-losing-market-support
Is Catalyst Pharmaceuticals Gaining or Los...
06/27/2025 19:00:22

top-3-health-care-stocks-youll-regret-missing-this-quarter
Top 3 Health Care Stocks You'll Regret Mis...
06/26/2025 12:15:48

catalyst-pharmaceuticals-affirms-fy2025-sales-guidance-of-54500m-56500m-vs-55724m-est
Catalyst Pharmaceuticals Affirms FY2025 Sa...
05/07/2025 20:50:43

Catalyst Pharmaceuticals (NASDAQ:CPRX) affirms FY2025 sales outlook from $545.00 million-$565.00 million to $545.00 million-$56...

catalyst-pharmaceuticals-q1-adj-eps-068-beats-053-estimate-sales-14142m-beat-13086m-estimate
Catalyst Pharmaceuticals Q1 Adj. EPS $0.68...
05/07/2025 20:50:23

Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate...

Core News & Articles
Earnings Scheduled For May 7, 2025
05/07/2025 08:33:08

catalyst-pharmaceuticals-announces-health-canada-acceptance-of-agamree-new-drug-submission-with-priority-review-for-sub-licensee-kye-pharmaceuticals
Catalyst Pharmaceuticals Announces Health ...
04/08/2025 12:07:33

celsius-lucid-and-signet-are-among-top-10-mid-cap-gainers-last-week-mar-17-mar-21-are-the-others-in-your-portfolio
Celsius, Lucid And Signet Are Among Top 10...
03/23/2025 21:28:30

Top performers last week: DGNX (108.29%), NEXT (25.07%), CELH (21.60%), SIG (21.08%), NFE (20.63%), MRP (16.61%), ARQT (16.35%)...

baird-maintains-outperform-on-catalyst-pharmaceuticals-raises-price-target-to-32
Baird Maintains Outperform on Catalyst Pha...
03/03/2025 12:45:33

Baird analyst Joel Beatty maintains Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Outperform and raises the price target fro...

hc-wainwright--co-reiterates-buy-on-catalyst-pharmaceuticals-maintains-35-price-target
HC Wainwright & Co. Reiterates Buy on Cata...
02/28/2025 14:22:11

HC Wainwright & Co. analyst Andrew Fein reiterates Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and maintains $35 p...

catalyst-pharmaceuticals-stock-a-deep-dive-into-analyst-perspectives-4-ratings
Catalyst Pharmaceuticals Stock: A Deep Div...
02/27/2025 18:00:22

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION